短程姑息性放射治疗对胰腺癌相关疼痛的影响:前瞻性2期非随机PAINPANC试验
这项前瞻性2期单中心非随机试验纳入30例中度至重度胰腺癌相关疼痛且止痛药难治的患者,接受24 Gy分3次每周照射的短程姑息放疗(2015-2018年)。结果显示疼痛在7周内平均降低3.15分(单侧P=0.045),全球生活质量从50.5显著改善至60.8(P=0.001),3级急性毒性3例,无4-5级毒性,中位总生存11.8周。
要点
- 短程姑息放疗24 Gy分3次每周照射与疼痛快速、有临床意义的减轻相关。
- 全球生活质量从50.5显著改善至60.8(P=0.001)。
- 3级急性毒性3例,无4-5级毒性;中位总生存11.8周,1年实际生存率13.3%。
核心结论
- 短程姑息性放射治疗与胰腺癌相关疼痛快速、有临床意义的减轻相关,并伴全球生活质量有临床意义的改善,毒性多为轻度。
研究设计与样本
- 前瞻性2期单中心非随机试验,纳入30例中度至重度(0-10量表5-10分)胰腺癌相关疼痛且止痛药难治的患者,接受24 Gy分3次每周照射的短程姑息放疗(2015-2018年)。
主要发现
- 30例中29例(96.7%)接受了姑息放疗。
- 基线中位口服吗啡等效日剂量为129.5 mg(范围20.0-540.0 mg),放疗后降至75.0 mg(范围15.0-360.0 mg)(P=0.021)。
- 疼痛从基线至7周平均降低3.15分(单侧P=0.045)。
- 患者报告疼痛严重程度在最初3周内从5.9分有临床意义地降至3.8分(P=0.011),至第11周进一步降至3.2分,至首次放疗分次后第21周最终为3.4分(P=0.006)。
- 全球生活质量在随访期间从50.5显著改善至60.8(P=0.001);3级急性毒性3例,未观察到4-5级毒性;中位总生存11.8周,1年实际生存率13.3%。
关键数值与推荐
- 主要终点定义为治疗开始后7周内疼痛严重程度较基线平均降低≥2分(有临床意义)。
- 次要终点为全球生活质量,以5-10分(0-100量表)的增加为有临床意义。
- 疼痛严重程度和生活质量分别使用简明疼痛评估量表(Brief Pain Inventory)和欧洲癌症研究与治疗组织生活质量问卷-C15-PAL(EORTC QLQ-C15-PAL)评估9次,均采用联合模型分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical evidence is limited regarding palliative radiation therapy for relieving pancreatic cancer-related pain. We prospectively investigated pain response after short-course palliative radiation therapy in patients with moderate-to-severe pancreatic cancer-related pain. METHODS AND MATERIALS: In this prospective phase 2 single center nonrandomized trial, 30 patients with moderate-to-severe pain (5-10, on a 0-10 scale) of pancreatic cancer refractory to pain medication, were treated with a short-course palliative radiation therapy; 24 Gy in 3 weekly fractions (2015-2018). Primary endpoint was defined as a clinically relevant average decrease of ≥2 points in pain severity, compared with baseline, within 7 weeks after the start of treatment. Secondary endpoint was global quality of life (QoL), with a clinically relevant increase of 5 to 10 points (0-100 scale). Pain severity reduction and QoL were assessed 9 times using the Brief Pain Inventory and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C15-PAL, respectively. Both outcomes were analyzed using joint modeling. In addition, acute toxicity based on clinician reporting and overall survival (OS) were assessed. RESULTS: Overall, 29 of 30 patients (96.7%) received palliative radiation therapy. At baseline, the median oral morphine equivalent daily dose was 129.5 mg (range, 20.0-540.0 mg), which decreased to 75.0 mg (range, 15.0-360.0 mg) after radiation (P = .021). Pain decreased on average 3.15 points from baseline to 7 weeks (one-sided P = .045). Patients reported a clinically relevant mean pain severity reduction from 5.9 to 3.8 points (P = .011) during the first 3 weeks, which further decreased to 3.2 until week 11, ending at 3.4 (P = .006) in week 21 after the first radiation therapy fraction. Global QoL significantly improved from 50.5 to 60.8 during the follow-up period (P = .001). Grade 3 acute toxicity occurred in 3 patients and no grade 4 to 5 toxicity was observed. Median OS was 11.8 weeks, with a 13.3% 1-year actuarial OS rate. CONCLUSIONS: Short-course palliative radiation therapy for pancreatic cancer-related pain was associated with rapid, clinically relevant reduction in pain severity, and clinically relevant improvement in global QoL, with mostly mild toxicity.
引用
- Tello Valverde CP, Ebrahimi G, Sprangers MA, et al. Impact of Short-Course Palliative Radiation Therapy on Pancreatic Cancer-Related Pain: Prospective Phase 2 Nonrandomized PAINPANC Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37647972. doi:10.1016/j.ijrobp.2023.08.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。